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Aims: Sodium glucose co-transporter 2 (SGLT2) inhibitors reduce several cardiovas-
cular risk factors, including plasma glucose, blood pressure, albuminuria and body
weight. Long-term treatment lowers risks of cardiovascular and renal events. The
objective of this post hoc analysis was to determine the effects of canagliflozin treat-
ment versus placebo on clinical outcomes in relation to body mass index (BMI).
Materials and methods: The CANVAS Program randomized 10 142 participants with
type 2 diabetes to canagliflozin or placebo. These analyses tested the consistency of can-
agliflozin treatment effects across BMI levels for cardiovascular, renal, safety and body
weight outcomes in three groups defined by baseline BMI: <25, 25-<30 and ≥30 kg/m2.
Results: In total, 10 128 participants with baseline BMI measurements were included.
There were 966 participants with BMI <25 kg/m2, 3153 with BMI 25-<30 kg/m2 and
6009 with BMI ≥30 kg/m2. Mean percent body weight reduction with canagliflozin
compared with placebo was greater at 12 months [−2.77% (95% confidence interval
(CI): −2.95, −2.59)] than at 3 months [−1.72% (95% CI: −1.83, −1.62)]. The hazard
ratios (HRs) for canagliflozin compared with placebo control for the composite out-
come of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke
were 1.03 (95% CI: 0.66, 1.59) in participants with BMI <25 kg/m2, 0.97 (0.76, 1.23)
with BMI 25-<30 kg/m2 and 0.79 (0.67, 0.93) with BMI ≥30 kg/m2 (P for heteroge-
neity = 0.55). The effects of canagliflozin on each component of the composite were
also similar across BMI subgroups, as were effects on heart failure and renal out-
comes (P for heterogeneity ≥0.19). The effects on safety outcomes were also broadly
similar.
Conclusions: Canagliflozin improved cardiovascular and renal outcomes consistently
across patients with a broad range of BMI levels.
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DOI: 10.1111/dom.13920
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
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1 | INTRODUCTION
Both type 2 diabetes and obesity are epidemics causing major global pub-
lic health problems.1 Excess body fat is a major contributor to the develop-
ment of type 2 diabetes, as well as cardiovascular (CV) disease and
premature death.2-8 Given the benefits of weight loss in the prevention
and treatment of type 2 diabetes,9,10 weight management is rec-
ommended for patients with type 2 diabetes who are overweight or
obese.11 One of the more important considerations in deciding on an
appropriate antihyperglycaemic agent is its effects on body weight.11
Sodium glucose co-transporter 2 (SGLT2) inhibitors lower blood
glucose levels by reducing the renal threshold for glucose and increas-
ing urinary glucose excretion.12 In addition, SGLT2 inhibitors improve
other CV risk factors, including blood pressure (BP), albuminuria and
body weight. Reductions in body weight may be achieved both
through loss of calories and through natriuresis. Moderate and
sustained reductions in body weight were observed in the EMPA-REG
OUTCOME trial,13,14 the CANVAS (CANagliflozin cardioVascular
Assessment Study) Program15,16 and the DECLARE-TIMI 58 trial.17
The same trials demonstrated that SGLT2 inhibitors reduced the risk
of CV and renal events. However, whether the effects of SGLT2
inhibitors on weight loss vary according to participant characteristics
and whether the benefits of SGLT2 inhibitors differ among patients
with differences in body mass index (BMI) are unknown.
The objectives of this post hoc analysis were to determine whether
the effects of the SGLT2 inhibitor canagliflozin on CV outcomes, renal
outcomes, body weight and safety indicators vary according to baseline
BMI levels, using data from the CANVAS Program.
2 | MATERIALS AND METHODS
2.1 | Ethics
CANVAS and CANVAS-Renal (CANVAS-R; ClinicalTrials.gov registra-
tion numbers NCT01032629 and NCT01989754) were approved by
the institutional review board for each centre, and all participants pro-
vided written informed consent. All procedures followed were in
accordance with the Declaration of Helsinki 1964, as revised in 2013.
2.2 | Study design and participants
The CANVAS Program, comprising two similarly designed and conducted
large-scale double-blind trials, CANVAS and CANVAS-R, assessed the CV
and renal efficacy and safety of canagliflozin compared with placebo. A
detailed description of the design and the main results of the CANVAS
Programwere previously published.15,18 In brief, 10 142 participants with
type 2 diabetes and a history or high risk of CV diseasewere enrolled from
667 centres in 30 countries. The individuals included men and women
with type 2 diabetes [haemoglobin A1c (HbA1c) ≥7.0% and ≤10.5%] who
were either ≥30 years of age with a history of symptomatic atheroscle-
rotic CV disease or ≥50 years of age with ≥2 of the following risk factors
for CV disease: duration of diabetes mellitus ≥10 years, systolic BP
>140 mmHgwhile receiving ≥1 antihypertensive agents, current smoking,
microalbuminuria or macroalbuminuria or high-density lipoprotein choles-
terol <1 mmol/L. Participants were required to have an estimated glomer-
ular filtration rate (eGFR) of ≥30 mL/min/1.73 m2 at entry, but therewere
no specific bodyweight-related inclusion criteria.
2.3 | Randomized treatment and follow-up
After a 2-week, single-blind, placebo run-in period, participants in CAN-
VAS were randomly assigned in a 1:1:1 ratio to receive once-daily can-
agliflozin 100 mg, canagliflozin 300 mg or placebo, while participants in
CANVAS-R were randomly assigned in a 1:1 ratio to receive once-daily
canagliflozin 100 mg or matching placebo, with an optional uptitration to
300 mg starting at week 13, through a central web-based system with
the use of a computer-generated randomization schedule with randomly
permuted blocks. Participants were required to have stable background
glucose-lowering therapy for 8 weeks before screening and wherever
possible to persist with this treatment regimen unchanged for the first
18 weeks after randomization in CANVAS.19 Beyond 18 weeks in CAN-
VAS and throughout CANVAS-R, background drug treatments for glu-
cose control were at the discretion of the responsible investigator, with
the exception of SGLT2 inhibitors.19,20 All participants and trial staff
were blinded to individual treatment allocations until the end of the trial.
Participants were followed at least three times in the first year and at
6-month intervals thereafter until the end of the study, with telephone
follow-up between face-to-face assessments.
2.4 | Body mass index
BMI was calculated from height and body weight. For this analysis,
participants were classified into three groups based on BMI at base-
line: <25, 25-<30 and ≥30 kg/m2. Only participants with baseline BMI
measurements were included in this analysis.
2.5 | Outcomes
The primary outcome for the CANVAS Program was a composite of
death from CV causes, non-fatal myocardial infarction (MI) or non-fatal
stroke. Secondary outcomes included death from CV causes, fatal or
non-fatalMI, fatal or non-fatal stroke, hospitalization for heart failure and
a composite renal outcome of 40% decrease in eGFR, end-stage
kidney disease or renal death. This analysis also assessed effects on the
intermediate outcomes, including HbA1c, systolic BP, body weight, urine
albumin/creatinine ratio (UACR) and eGFR. In addition, the effects on key
safety outcomes were determined. Safety outcomes included adverse
events coded using the latest version of the Medical Dictionary for Regu-
latory Activities (MedDRA) at the time of the database lock.15 Both seri-
ous and non-serious adverse events were collected for the CANVAS
trial until early 2014, as mandated by the US Food and Drug Administra-
tion and other regulatory bodies for initial approval of canagliflozin.
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Age, years (mean ± SD) 64.0 ± 8.9 63.9 ± 8.5 62.8 ± 8.0 <0.001
Sex, n (%) <0.001
Female 328 (33.95) 980 (31.1) 2319 (38.6)
Male 638 (66.05) 2173 (68.9) 3690 (61.4)
Race, n (%) <0.001a
White 443 (45.9) 2273 (72.1) 5220 (86.9)
Asian 404 (41.8) 590 (18.7) 288 (4.8)
Black or African American 32 (3.3) 82 (2.6) 219 (3.6)
Otherb 87 (9.0) 208 (6.6) 282 (4.7)
Current smoker, n (%) 193 (20.0) 595 (18.9) 1017 (16.9) 0.003
History of hypertension, n (%) 782 (81.0) 2749 (87.2) 5580 (92.9) <0.001
History of heart failure, n (%) 87 (9.0) 381 (12.1) 992 (16.5) <0.001
Duration of diabetes, years
(mean ± SD)
14.2 ± 8.3 13.6 ± 7.7 13.4 ± 7.7 0.004
Drug therapy, n (%)
Insulin 359 (37.2) 1383 (43.9) 3346 (55.7) <0.001
Sulphonylurea 562 (58.2) 1513 (48.0) 2280 (37.9) <0.001
Metformin 725 (75.1) 2426 (76.9) 4665 (77.6) 0.09
GLP-1 receptor agonist 4 (0.4) 68 (2.2) 333 (5.5) <0.001
DPP-4 inhibitor 130 (13.5) 427 (13.5) 702 (11.7) 0.01
Statin 662 (68.5) 2317 (73.5) 4608 (76.7) <0.001
Antithrombotic 690 (71.4) 2293 (72.7) 4476 (74.5) 0.01
RAAS inhibitor 671 (69.5) 2400 (76.1) 5033 (83.8) <0.001
Beta-blocker 392 (40.6) 1559 (49.4) 3466 (57.7) <0.001
Diuretic 267 (27.6) 1108 (35.1) 3109 (51.7) <0.001
Microvascular disease history, n (%)
Retinopathy 179 (18.6) 634 (20.1) 1314 (21.9) 0.005
Nephropathy 159 (16.5) 503 (16.0) 1110 (18.5) 0.007
Neuropathy 250 (25.9) 867 (27.5) 1990 (33.1) <0.001
Atherosclerotic vascular diseasec
Coronary 494 (51.1) 1795 (56.9) 3423 (57.0) 0.01
Cerebrovascular 162 (16.8) 607 (19.3) 1186 (19.7) 0.06
Peripheral 184 (19.1) 668 (21.2) 1258 (20.9) 0.39
Any 675 (69.9) 2294 (72.8) 4344 (72.3) 0.35
CV disease history, n (%)d 642 (66.5) 2113 (67.0) 3890 (64.7) 0.06
History of amputation, n (%) 25 (2.6) 62 (2.0) 149 (2.5) 0.52
BMI, kg/m2 (mean ± SD) 23.1 ± 1.5 27.7 ± 1.4 35.6 ± 4.7 <0.001
Systolic BP, mmHg (mean ± SD) 133.6 ± 16.9 135.4 ± 15.8 137.8 ± 15.4 <0.001
Diastolic BP, mmHg (mean ± SD) 75.8 ± 9.1 77.1 ± 9.4 78.3 ± 9.8 <0.001
HbA1c, % (mean ± SD) 8.2 ± 1.0 8.2 ± 0.9 8.3 ± 0.9 0.01
Total cholesterol, mmol/L (mean ± SD) 4.30 ± 1.12 4.35 ± 1.13 4.38 ± 1.17 0.06
Triglycerides, mmol/L (mean ± SD) 1.62 ± 1.17 1.91 ± 1.32 2.15 ± 1.48 <0.001
HDL-C, mmol/L (mean ± SD) 1.25 ± 0.35 1.19 ± 0.32 1.16 ± 0.30 <0.001
LDL-C, mmol/L (mean ± SD) 2.33 ± 0.92 2.31 ± 0.93 2.28 ± 0.94 0.051
LDL-C/HDL-C ratio (mean ± SD) 1.97 ± 0.89 2.04 ± 0.92 2.06 ± 0.93 0.008
(Continues)
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Thereafter, following registration of the drug, only serious adverse
events, adverse events leading to study drug discontinuation, and selected
adverse events of interest were collected across the CANVAS Program.
All major CV, renal and selected safety outcomes were adjudicated by
central endpoint adjudication committees blinded to treatment allocation.
Detailed definitions for the outcomes were previously published.15
2.6 | Statistical methods
Differences in baseline characteristics across BMI categories were
tested by linear regression analysis or logistic regression analysis, as
appropriate. Cox regression models were used to estimate hazard
ratios (HRs) and their corresponding 95% confidence intervals (CIs)
for the primary and other CV and renal outcomes, with stratification
according to trial and history of CV disease (for CV outcomes) and
baseline eGFR level (<60 or ≥60 mL/min/1.73 m2) as the exploratory
variable (for the main renal outcome) using an intention-to-treat
approach, for all canagliflozin groups combined versus placebo. Safety
outcomes were analysed using an on-treatment approach (with data
based on participants who had a safety outcome while they were
receiving study drug, or within 30 days after discontinuation of study
drug), except for amputation, fracture and diabetic ketoacidosis out-
comes, where analyses included participants who received ≥1 dose of
study drug and had an event at any time during follow-up. Annualized
incidence rates were calculated per 1000 patient-years of follow-up.
The effects of canagliflozin on continuous outcomes (HbA1c, systolic
BP, body weight, eGFR) were calculated as mean change from base-
line across the entire follow-up period. The average change in these
continuous outcomes over time and the difference between can-
agliflozin and placebo (placebo-subtracted differences) were analysed
using mixed-effects models for repeated measurements that included
all the post-baseline data up to week 312, assuming that missing data
were missing at random, and the covariates for study, visit, treatment
and baseline values. UACR was log-transformed because of its
skewed distribution, and the geometric mean of post-baseline UACR
was estimated using a similar mixed-effects model. Changes in albu-
minuria were calculated as the ratio of the geometric mean of post-
randomization UACR measures with canagliflozin compared with pla-
cebo. Early percentage change in body weight over 12/13 weeks or
over 52 weeks and the difference between canagliflozin and placebo
were also evaluated using linear regression analysis with study and
treatment as covariates. Heterogeneity of treatment effect across sub-
groups defined by baseline BMI levels was tested by: (a) adding sub-
group and a term for subgroup by treatment interaction to the relevant
model, (b) testing for a linear trend across the subgroups and
(c) including a treatment-by-BMI interaction term in the model. The
global P values for heterogeneity across subgroups were obtained
through the likelihood ratio test. Statistical analyses were performed
with the SAS Enterprise Guide, version 7.11 (SAS Institute, Cary, North
Carolina) and Stata software (release 13; StataCorp, College Station,
Texas). A two-sided P <0.05 was considered statistically significant. No
adjustments for multiple statistical comparisons were made.
3 | RESULTS
3.1 | Patient characteristics
Of the 10 142 patients who participated in the CANVAS Program,
10 128 (99.9%) had baseline BMI measurements and were included in
this analysis. Baseline characteristics according to baseline BMI levels
are shown in Table 1. Patients with higher BMI tended to smoke less
but were more frequently white, or had a diagnosis of hypertension or
heart failure; this group also reported greater use of multiple drug
therapies for glucose control and CV disease prevention, but less sul-
phonylurea use. Patients with higher BMI had greater prevalence of
retinopathy, nephropathy and neuropathy and had higher measured
values of BP and triglyceride levels. Levels of high-density lipoprotein
cholesterol and eGFR were lower among those with higher BMI.
Baseline characteristics across canagliflozin and placebo groups in










eGFR, mL/min/1.73 m2 (mean ± SD) 78.5 ± 22.2 77.1 ± 20.3 75.8 ± 20.3 <0.001
UACR, mg/g, median (IQR) 13.1 (7.2, 46.9) 11.6 (6.5, 34.2) 12.6 (6.6, 45.7) 0.77
Albuminuria 0.07a
Normoalbuminuria, n (%) 659 (68.5) 2265 (72.8) 4075 (68.6)
Microalbuminuria, n (%) 213 (22.1) 634 (20.4) 1415 (23.8)
Macroalbuminuria, n (%) 90 (9.4) 214 (6.9) 454 (7.6)
Abbreviations: BMI, body mass index; BP, blood pressure; CV, cardiovascular; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration rate;
GLP-1, glucagon-like peptide-1; HbA1c, haemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; IQR, interquartile range; LDL-C, low-density
lipoprotein cholesterol; RAAS, renin-angiotensin-aldosterone system; SD, standard deviation; UACR, urinary albumin/creatinine ratio.
aP values for race and albuminuria were derived from the chi-squared test.
bIncludes American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, multiple, other and unknown.
cSome participants had >1 type of atherosclerotic disease.
dAs defined in the protocol.
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3.2 | Cardiovascular and renal outcomes
Overall, canagliflozin significantly reduced the risk of the composite
CV outcome [CV death, non-fatal MI or non-fatal stroke; HR 0.86
(95% CI: 0.75, 0.97); Figure 1] compared with placebo, with no signifi-
cant heterogeneity across subgroups defined by baseline BMI. The
HRs for canagliflozin compared with placebo were 1.03 (95% CI: 0.66,
1.59) in patients with BMI <25 kg/m2, 0.97 (95% CI: 0.76, 1.23) in
patients with BMI 25-<30 kg/m2, and 0.79 (95% CI: 0.67, 0.93) in
patients with BMI ≥30 kg/m2 (P for heterogeneity = 0.55). This associ-
ation was unchanged when patients with BMI ≥30 kg/m2 were further
split into those with BMI 30-<40 and ≥40 kg/m2; HRs were 0.79 (95%
CI: 0.66, 0.94) in the 5071 with BMI 30-<40 kg/m2 and 0.82 (95% CI:
0.56, 1.20) in the 938 with BMI ≥40 kg/m2 (P for heterogeneity = 0.72).
F IGURE 1 Effects of canagliflozin compared with placebo on CV and renal outcomes across the CANVAS Program according to baseline BMI
levels. Abbreviations: BMI, body mass index; CI, confidence interval; CV, cardiovascular; eGFR, estimated glomerular filtration rate; ESKD,
end-stage kidney disease; HF, heart failure; HR, hazard ratio; MI, myocardial infarction
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Furthermore, no heterogeneity in the effects was identified between
Asian and non-Asian patients with BMI <25 kg/m2 (P for heterogene-
ity = 0.86). The effect of canagliflozin was also consistent across BMI
subgroups for deaths from CV causes, fatal or non-fatal MI, fatal or
non-fatal stroke, hospitalization for heart failure and the composite
renal outcome (all P for heterogeneity ≥0.19). When assessed as an
interaction fitting baseline BMI as a continuous variable, significant
heterogeneity was observed for fatal or non-fatal stroke (P for hetero-
geneity = 0.02) but not for any other outcome (all P for heterogeneity
≥0.14). Absolute risk reductions for CV and renal outcomes were also
similar across BMI subgroups (P for heterogeneity ≥0.09; Figure 1).
3.3 | Intermediate markers
Irrespective of BMI, canagliflozin compared with placebo decreased
HbA1c, systolic BP, UACR and eGFR. The placebo-subtracted mean dif-
ferences in these intermediate markers were constant across BMI sub-
groups (all P for heterogeneity ≥0.09), except for body weight, where a
greater absolute reduction in weight was observed among those with
baseline BMI ≥30 kg/m2 (P for heterogeneity <0.001; Figure 2). There
were, however, no differences in effects across BMI subgroups if per-
centage weight loss was assessed (P for heterogeneity = 0.17).
The overall effects on percentage body weight varied substan-
tially over time with canagliflozin use compared with placebo,
resulting in a greater reduction at 12 months [−2.77% (95% CI: −2.95,
−2.59); Figure S1 (see Supporting Information)] than at 3 months
[−1.72% (95% CI: −1.83, −1.62)]. There was evidence that percentage
weight reductions at 3 months were significantly greater with the
300 mg [−2.17% (95% CI: −2.35, −1.99)] compared with 100 mg
[−1.67% (95% CI: −1.86, −1.49)] dose of canagliflozin (P <0.001 for
the difference between the canagliflozin 100 mg and 300 mg groups
in CANVAS). The same was true at 12 months for 300 mg [−3.28%
(95% CI: −3.62, −2.95)] and for 100 mg [−2.54% (95% CI: −2.87,
−2.21)] (P <0.001). At both time points there were greater percentage
body weight reductions achieved among patients with no history of
heart failure, and those using insulin or a glucagon-like peptide-1
(GLP-1) receptor agonist but not a sulphonylurea (all P for trend
<0.05). Effects at 3 months alone were also greater for those without
a history of hypertension and those with a lower baseline HbA1c
(all P for trend <0.05). Early effects according to baseline eGFR
showed a lesser effect on body weight among those with eGFR
45-<60 mL/min/1.73 m2 but comparable effects on those with either
higher or lower levels of eGFR.
3.4 | Safety outcomes
The effects of canagliflozin on safety outcomes are shown in Figure 3
and Figure S2 (see Supporting Information). The risks of adverse
events were consistent across the subgroups defined by baseline BMI
(P for heterogeneity ≥0.15) with the exception of urinary tract infec-
tion (P for heterogeneity = 0.01), the risk for which appeared greater
among patients with baseline BMI 25-<30 kg/m2 but not among
patients with baseline BMI <25 or ≥30 kg/m2. This heterogeneity was
not observed in the analyses using BMI as a continuous variable (P for
interaction = 0.83).
4 | DISCUSSION
In this large-scale randomized, controlled trial of patients with
type 2 diabetes, reductions in the risks of CV and renal events
achieved with canagliflozin were consistent across subgroups defined
by baseline BMI levels of <25, 25-<30 and ≥30 kg/m2. Effects of can-
agliflozin on safety outcomes were also broadly similar across these
subgroups. Overall, our findings suggest that CV and renal protective
benefits of canagliflozin are not modified by baseline BMI levels, and
further highlight the value of this therapy for CV disease prevention
among obese, overweight and leaner patients.
Higher BMI is associated with increased levels of circulating free
fatty acids and greater accumulations of harmful visceral, hepatic,
skeletal, intracardial and epicardial fat.21-23 In particular, epicardial adi-
pose tissue surrounding the heart generates pathogenic mechanical,
endocrinological, immunological, paracrine and vasocrine signalling, all
of which may contribute to heart failure—particularly heart failure
with preserved ejection fraction.24 Individuals with diabetes and
higher baseline BMI may also have greater sodium and fluid retention
and might achieve enhanced protection from SGLT2 inhibitor therapy
because of the known natriuretic effects of the class. Therefore, there
was a rationale for anticipating potentially greater effects of can-
agliflozin on clinical outcomes among patients with higher BMI at
baseline.
The CANVAS Program findings of comparable effectiveness of
SGLT2 inhibition for the prevention of CV and renal outcomes across
BMI subgroups align with similar observations from the EMPA-REG
OUTCOME trial13 and the DECLARE-TIMI 58 trial.17 Although small
differences in protection between those with higher versus lower
BMI may have gone undetected by these studies, these observations
suggest that BMI level does not substantively modify the prevention
of CV events by canagliflozin. The significant interaction observed for
fatal or non-fatal stroke when BMI was fitted as a continuous variable
may be a chance finding consequent upon the number of statistical
tests conducted. Further studies focusing on relatively lean patients
might better elucidate this issue. The evidence of benefit observed for
the BMI category of <25 kg/m2 may be of particular relevance to
Asian populations, and while BMI may be an imperfect measure of
adiposity among individuals of Asian ethnicity, there is an epidemic of
obesity and type 2 diabetes in Asian populations, which occurs at rela-
tively low BMI.25,26 CV protection with SGLT2 inhibition at lower
levels of BMI provides some reassurance about the likely impact of
this drug class among Asians with type 2 diabetes irrespective of BMI.
The effects of canagliflozin on safety outcomes were also consis-
tent across BMI subgroups. Canagliflozin increased the risks of ampu-
tation, genital infections, diabetic ketoacidosis, osmotic diuresis and
volume depletion, but effects were not modified by baseline BMI. The
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F IGURE 2 Effects of canagliflozin compared with placebo on intermediate markers of CV risk across the CANVAS Program according to
baseline BMI levels. Abbreviations: BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, haemoglobin
A1c; UACR, urinary albumin/creatinine ratio
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F IGURE 3 Effects of canagliflozin compared with placebo on safety outcomes across the CANVAS Program according to baseline BMI levels.
Abbreviations: BMI, body mass index; CI, confidence interval; HR, hazard ratio
OHKUMA ET AL. 537
heterogeneity observed for urinary tract infection appears to be attrib-
utable to chance, with no plausible explanation identified as to
why there might be an increased risk among the BMI subgroup
25-<30 kg/m2, but not among those with higher or lower BMI values.
Weight loss due to glycosuria is a unique characteristic of
SGLT2 inhibitors27 and, although not previously identified as a
strong independent mediator of CV protection,28 is clearly viewed
as an important benefit by both patients and clinicians.29 These ana-
lyses identified that percentage reductions in body weight with can-
agliflozin therapy were consistent across different initial levels of
BMI. Greater weight loss was associated with several patient char-
acteristics, including absence of a history of heart failure or hyper-
tension, use of insulin, use of GLP-1 agonist and non-use of a
sulphonylurea, but the mechanism for the greater percentage reduc-
tion in weight loss in these patients was not apparent. Similarly
unclear was the reason why weight reductions in this study and a
previous report30 were greater among those with lower baseline
HbA1c levels at 3 months—the opposite might have been antici-
pated, as renal excretion of glucose and calories with SGLT2 inhibi-
tion would be lower among those with well-controlled glycaemia.31
The observed differences in weight reduction between eGFR sub-
groups were not linearly associated with renal function as might
have been expected.27 The greater effect of canagliflozin on weight
at 12 months versus at 3 months probably reflects dual mechanisms
of weight loss that are additive over time. Early reductions in body
weight are likely to be driven primarily by fluid excretion resulting
from the known natriuretic effects of the compound, with subse-
quent additional reduction in body weight attributable mostly to
caloric loss and associated reduction in fat mass.32
The strengths of this analysis include the large and diverse patient
population derived from an international, multicentre randomized trial
conducted to a high standard, with a long duration of follow-up and
rigorous adjudication of the main outcomes. It is of note that the con-
clusions about consistency of effects were not substantively different
when assessed using measures of trend across either BMI categories
or BMI fitted as a continuous variable. Limitations include the rela-
tively small number of participants with BMI <25 kg/m2, which
reduced the statistical power to draw definite conclusions regarding
treatment effects in leaner patients. In addition, the large number of
statistical tests without correction for multiple comparisons may have
resulted in spurious false-positive findings.
In conclusion, canagliflozin reduced the risk of CV and renal
events in patients with type 2 diabetes, with consistent effects across
subgroups defined by baseline BMI levels. However, the effects on
body weight were different across patient subsets. These data indi-
cate beneficial effects of canagliflozin in preventing CV and renal
complications irrespective of the presence or absence of obesity.
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